Navigation Links
VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Date:6/11/2009

Safety and Biologic Activity Data Reviewed in End of Phase 2a Meeting

SAN FRANCISCO, June 11 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, announced today that an end of Phase 2a meeting for the Company's lead drug, VIA-2291 (atreleuton), was recently held with the U.S. Food and Drug Administration (FDA). The Company reviewed safety and biologic activity data from the VIA-2291 Phase 2 CEA and ACS trials with the FDA and received guidance including suggestions from the Agency on the Company's Phase 3 trial design.

VIA-2291 is a selective and reversible inhibitor of 5 Lipoxygenase, a key enzyme in the biosynthesis of leukotrienes, which are important mediators of the inflammation believed to be involved in the development and progression of atherosclerosis. The Company's Phase 3 cardiovascular outcome study will assess the effect of VIA-2291 in preventing cardiovascular events such as heart attack, stroke and cardiovascular mortality in patients with recent heart attack and/or established atherosclerotic cardiovascular disease. Guidance from the FDA will be incorporated into the VIA-2291 registration and Phase 3 program, and the company intends to submit its proposed Phase 3 plan to FDA including a request for a Special Protocol Assessment. The Company is currently exploring strategic opportunities for launching this final phase of development.

"The current treatment approaches have reached their potential, and yet there still exists a significant unmet medical need in heart disease, particularly in patients at high risk for heart attacks, strokes and cardiovascular death," said Larry Cohen, President and Chief Executive Officer of VIA Pharmaceuticals, Inc. "VIA-2291 specifically
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
2. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
3. ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
4. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
5. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
6. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
7. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
8. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
9. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
10. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... luglio 2014 ResMed (NYSE: RMD ... la cura dei disturbi respiratori del sonno (SDB) e ... permanente in Germania contro il produttore Taiwanese di dispositivi ... di apparecchiature da indossare in testa, che violano i ... 220. La sentenza della Corte Regionale Distrettuale di ...
(Date:7/28/2014)... OXFORD, England , July 28, 2014 ... bekannt, dass Albion Ventures 2,5 Millionen £ ... Kundenautomatisierungsmanagement in der Konsumgüter-, Gesundheits-, Pharma- und ... Shackleton Ventures.      (Photo: ... letzten 18 Monaten hat OmPrompt sein beschleunigtes ...
(Date:7/28/2014)... INCLINE VILLAGE, Nev. , July 28, 2014 ... announced that the Company will release its second quarter 2014 ... Monday, August 11, 2014, after market close. PDL,s management will ... p.m. Eastern Time to discuss the financial results.  A slide ... webcast link on the PDL website. Conference Call ...
Breaking Medicine Technology:ResMed riceve un'ingiunzione permanente contro APEX in Germania, continua a far valere i propri diritti per i brevetti in Europa 2OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2
... 2012  PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... March 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20111025/LA93174LOGO-c ... loss from continuing operations of $513,000, or $0.16 per ... compared to income from continuing operations of $909,000, or ...
... OAKS, Calif., May 4, 2012  Amgen (NASDAQ: AMGN ... Wednesday, May 9, 2012, at the Four Seasons Hotel, Chicago, ... vice president of Investor Relations at Amgen, will present. Live ... Calendar on Amgen,s website, www.amgen.com , under Investors. ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 2Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 3Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 4Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 5Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 6Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 7Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 8
(Date:7/28/2014)... CA (PRWEB) July 28, 2014 At some ... uncomfortable situation where they’re forced to contact the authorities. ... more difficult than it initially seems. , Not every dangerous ... vehicle get stolen, a person get mugged, or a bank ... less obvious, leading onlookers to be more passive than they ...
(Date:7/28/2014)... The report “Industrial Enzymes Market by Types (Carbohydrase, ... Bio-Fuel, Animal Feed), & Geography - Global Trends ... global industrial enzymes market with analysis and forecasting ... also identifies driving and restraining factors for the ... opportunities, burning issues, winning imperatives, and challenges. The ...
(Date:7/28/2014)... July 28, 2014 "Fist bumping" transmits significantly ... still addressing the cultural expectation of hand-to-hand contact ... published in the August issue of the ... publication of the Association for Professionals in Infection ... from the Institute of Biological, Environmental, and Rural ...
(Date:7/28/2014)... Qualis Health, one of the ... has published a complimentary, online toolkit that provides ... and families in infection control. Tested and ... toolkit provides a step-by-step roadmap for implementing an ... families early in a hospital stay. , “Across ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Recent research ... desk all day for years can lead to a ... cardiovascular disease. But using a standing desk, or an ... pain, often driving office workers back to a seated ... are designed to alleviate this leg pain and ...
Breaking Medicine News(10 mins):Health News:Take Action To Protect Your Fellow Citizens 2Health News:Take Action To Protect Your Fellow Citizens 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:Fist-bumping beats germ-spreading handshake, study reports 2Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2Health News:New Standing Desk Anti-fatigue Mats from Martinson-Nicholls Reduce Leg Fatigue and Discomfort Working at Standing and Sit-to-Stand Desks 2
... brain may have problems in forming perception categories for// printed ... to the dyslexics finding it difficult to filter out visual ... of them. ,The research by the scientists from University ... the nature of the workings of a dyslexic brain. ...
... to lose knee lubrication following an injury to the knee. ... University of Rhode Island had identified a way to find ... knee after a knee injury, in order to find out ... ,Although knee injury is considered to be a risk ...
... that children are more exposed to indoor allergens// at ... that are commonly found indoor include bacteria, molds, mildew, ... cockroaches and pollens. These may cause allergic reactions like ... Some of the symptoms experienced by people in presence ...
... survived cancer may have higher risks of having cognitive// ... University of Southern California had found that patients who ... twice as much risk as their healthy counterparts of ... survivors of cancer and their twins with the help ...
... Canada helped in conceiving and// delivering world’s first baby ... mother of the baby had her eggs collected from ... thawed and fertilized from sperms of her partner through ... was implanted in her uterus, which she carried to ...
... constantly exposed to air pollutions of big// cities may ... ,Inhalation of polluted air of the metros can ... particles emitted from the cars, trucks, buses, tobacco smoke, ... the chromosome of the fetus. , ,The research ...
Cached Medicine News:
... I Direct to High Res SSP kits provide high ... tray. Locus specific typing on a single tray reduces ... Straight from genomic DNA to high resolution results, no ... typing with a single tray , Unique reaction pattern ...
... built-in bags as in a suspension file system, ... contacting the ethylene glycol and without having to ... easy handling and maximum surface freezing concurrently with ... relatively hot air under the lid does not ...
... 8624 is UL Listed, CSA ... Plasma Freezers safely store single ... cryoprecipitate. Recorders are standard. Cold ... (12.7cm) of foamed-inplace polyurethane insulation ...
... A small self-contained freezer complying with ... blood plasma. External finish is grey colorbond ... assisted lid opening to a 40-litre capacity ... an effective single gasket contacting a heated ...
Medicine Products: